Document:

Document

Exhibit 10.1
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential.  Triple asterisks denote omissions.

SECOND AMENDMENT TO THE
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
This Second Amendment (the “Second Amendment”) to the License, Development and Commercialization Agreement effective as of July 9, 2015, as amended by that certain First Amendment to the License, Development and Commercialization Agreement dated August 19, 2019 (the “Agreement” ) is by and between Mersana Therapeutics, Inc. (“Mersana”), with offices at 840 Memorial Dr., Cambridge, MA02139, USA, and Recepta Biopharma, S.A. (“Recepta”), with offices at Rua Tabapuã, 1123 conj 36, Itaim Bibi, São Paulo, SP, CEP 04533 – 014, Brazil, and is effective as of the date that it is fully executed by the Parties (the  “Second Amendment Effective Date”). Capitalized terms not otherwise defined herein shall have the definitions ascribed to them in the Agreement.
BACKGROUND
WHEREAS, the Parties have been in discussions regarding the payment of the First Product Milestone Payment for [***] (the “[***] Milestone Payment”) as provided in Section 5.2 of the Agreement;
WHEREAS, the Parties have been in discussions regarding supply and regulatory assistance with respect to the Licensed Products;
WHEREAS, in the interest of confirming the Parties’ understanding of these matters, the Parties have agreed to amend the Agreement as set forth herein:
NOW THEREFORE, in consideration of the foregoing recitals and other good and valuable consideration, the receipt and sufficiency of which is hereby agreed and acknowledged, and intending to be legally bound, the Parties hereby agree as follows:
1.Defined Terms. The following definitions are hereby added to Article 1 of the Agreement:
a.“UPLIFT Study” means that certain single-arm registration strategy to be conducted by Mersana to evaluate the safety and efficacy of XMT-1536 in platinum-resistant ovarian cancer patients who have received up to four lines of therapy.
b.“Required Diagnostic Kit” means any diagnostic kit that is used in connection with clinical trials by Mersana, for or required to be made available in connection with the commercialization by Mersana of, the Licensed Products that Mersana is selling to customers in the Territory.
c.“Supply Price” means (i) with respect to Licensed Products, the lower of (a) [***] and (b) the supply price that Mersana charges to any other Mersana licensee in another country or region of the Territory for Licensed Product with the same specifications as the Licensed Product that is being supplied to Recepta or (ii) with respect to Required Diagnostic Kits, [***].

2.Section 3.3.2 of the Agreement is hereby deleted in its entirety and replaced with the following:
a.Recepta Territory. With respect to each Licensed Product that receives Regulatory Approval in the Territory, Mersana will, or will cause one or more of its sublicensees to (in Mersana’s sole discretion), enter into one or more supply agreements under which Mersana or the applicable sublicensee(s) will supply Recepta or Recepta’s sublicensee(s) with  the Licensed Product and any Required Diagnostic Kit with respect to such Licensed Product for sale to end user customers in the Recepta Territory (the “Supply Agreement”). The Supply Agreement will provide that Mersana or its sublicensee(s) will supply Licensed Product and Required Diagnostic Kits (if applicable) to Recepta at the Supply Price and contain such mutually agreeable and commercially reasonable supply terms as the parties may mutually agree, including (a) minimum quantity obligations, lead times, and binding forecast mechanisms to enable Recepta to properly forecast and order required amounts of Licensed Product; (b) commercially reasonable remedies to address a supply failure or a supply shortage; and (c) other appropriate remedies, in each case, in a manner and under the circumstances mutually agreed by the Parties. Mersana will, or will cause one or more of its sublicensees to, negotiate such Supply Agreement in good faith and use Diligent Efforts to execute such Supply Agreement by [***]. Mersana will or will cause one or more of its sublicensees to submit to Recepta a first supply agreement draft [***] days before such date. For the avoidance of doubt, no royalties shall be payable to Recepta on account of sales of Licensed Products or Required Diagnostic Kits to Recepta or its distributors for sale to end user customers in the Recepta Territory and such sales shall not be factored into the calculation of Mersana Annual Net Sales for purposes of determining the royalty rate applicable to Net Sales of Licensed Products by Mersana or its sublicensees. If there is a Required Diagnostic Kit with respect to the Licensed Product, and Mersana is not the entity selling such Required Diagnostic Kit, then, in lieu of being required to supply such Required Diagnostic Kit to Recepta, Mersana will use Diligent Efforts to assist Recepta in obtaining direct supply of any such Required Diagnostic Kit from Mersana’s Third Party partner, if any, for such Required Diagnostic Kits.  If, after using Diligent Efforts, Recepta is unable to obtain a direct supply of any such Required Diagnostic Kit from Mersana’s Third Party partner, Mersana shall supply the Required Diagnostic Kit to Recepta at the Supply Price in accordance with the other provisions of this Agreement.
3.Section 4.2.1 of the Agreement is hereby deleted in its entirety and replaced with the following:
a.Subject to Section 3.1.2, Recepta shall be solely responsible for, and shall use Diligent Efforts in connection with, the submission of information to, communicating with, and seeking Regulatory Approvals for Licensed Products in the Recepta Territory and will keep Mersana informed of all significant issues arising therefrom and material developments with respect 
2

thereto. Recepta will take into account Mersana’s reasonable suggestions and comments with respect to the materials and information which Recepta decides to submit to ANVISA in respect of the Licensed Products in the Recepta Territory. If and to the extent access to information, data (including Clinical Trial results), or materials (including samples of the relevant Licensed Product to the extent required in connection with Recepta’s application for Regulatory Approval) to which Recepta is not otherwise afforded access hereunder is necessary for Recepta to obtain and/or maintain Regulatory Approval in the Recepta Territory, Recepta shall notify Mersana in writing and, within [***] after acceptance of the application for Regulatory Approval by the FDA, Mersana shall commence making such information, data and/or materials, to the extent in Mersana’s possession and Control, available to Recepta, and will make all such information, data and/or materials, to the extent in Mersana’s possession and Control, available to Recepta within a reasonable time period thereafter, it being understood that Recepta’s receipt, use and disclosure of such information, data and/or materials shall be subject to the terms, conditions and limitations of this Agreement. For clarity, the foregoing obligation to provide access to information, data, or materials will include information, data or materials in Mersana’s possession and Control that Mersana may have received from one or more contract manufacturers engaged by Mersana to manufacture Licensed Products. Upon reasonable prior written notice to Mersana, (a) ANVISA will be permitted to conduct an inspection of Mersana’s facilities where the Licensed Products are manufactured solely as relates to the manufacture of such Licensed Products and (b) Mersana will use reasonable efforts to allow ANVISA to conduct an inspection of its contract manufacturer(s)’ facilities where Licensed Products are manufactured.
4.Section 5.2 of the Agreement is hereby amended to delete, in its entirety, the Development milestone entitled [***] solely for the First Product and its related payment of [***] for the First Product.
5.The following Development milestones shall be added to the table in Section 5.2 of the Agreement:
									
	Development Milestones
	First Product
	Second Product

		Milestone Payment

	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

            The Parties agree that, notwithstanding Section 5.2 of the Agreement, the payment of [***], as described in the first row of the table above, shall be made on [***]. The payment of [***], as described in the second row of the table above, shall be made on [***], provided the UPLIFT Study is active (i.e. has not been terminated or put on clinical hold) or completed at such time. In the event that the second payment is deferred because the UPLIFT Study has been 
3

put on clinical hold, as provided in the previous sentence, the second payment shall become due [***]. In case the UPLIFT Study is terminated, outstanding amounts on the second payment, if not already paid, and the third payment as described in the table above, will be paid to Recepta upon [***].
6.Effect on Agreement. Except as modified as set forth herein, the Agreement remains in full force and effect. This Second Amendment and the Agreement represent the entire agreement about this subject matter and supersede prior negotiations or agreements. All prior agreements, understandings, representations, warranties, and negotiations between the Parties about the subject matter of this Second Amendment and the Agreement merge into this Second Amendment and the Agreement.
7.Binding Effect. This Second Amendment will be binding upon and inure to the benefit of the Parties and their respective permitted successors and assigns.
8.Authority. As of the Second Amendment Effective Date, each Party hereby represents and warrants that (a) it has the power and authority to execute and deliver this Second Amendment, (b) the execution, delivery, and performance of this Second Amendment by it has been duly authorized by all requisite corporate action, and (c) this Second Amendment has been duly executed and delivered on behalf of such Party and constitutes a legal, valid, and binding obligation of such Party and is enforceable against it in accordance with its terms.
9.Amendments. This Second Amendment may not be modified or amended, except by another agreement in writing executed by duly authorized signatories of each Party.
10.Counterparts. This Second Amendment may be executed in two or more counterparts, all of which taken together will be regarded as one and the same instrument. Each Party may execute this Second Amendment in AdobeTM Portable Document Format (PDF) sent by digital transmission. PDF signatures of authorized signatories of the Parties will be deemed to be original signatures, will be valid and binding upon the Parties, and, upon delivery, will constitute due execution of this Second Amendment.
[Signatures on following page]

4

IN WITNESS WHEREOF, Mersana and Recepta, by their duly authorized officers, have executed this Second Amendment.
															
	MERSANA THERAPEUTICS, INC.		RECEPTA BIOPHARMA S.A.
	By:	/s/ Brian DeSchuytner		By:	/s/ José Fernando Perez
	Name:	Brian DeSchuytner		Name:	José Fernando Perez
	Title:	SVP, Finance and Product Strategy		Title:	President
	Date:	September 28, 2021		Date:	September 28, 2021Document

Exhibit 10.1

 OMNIBUS JOINDER TO LOAN DOCUMENTS
This OMNIBUS JOINDER TO LOAN DOCUMENTS (this “Joinder”), dated as of November 5, 2021, is entered into by and among SYNALLOY CORPORATION, a Delaware corporation (“Synalloy”), CRI TOLLING, LLC, a South Carolina limited liability company (“CRI”), SYNALLOY FABRICATION, LLC, a South Carolina limited liability company (“Synalloy Fabrication”), MANUFACTURERS SOAP & CHEMICAL COMPANY, a Tennessee corporation (“Manufacturers Soap”), MANUFACTURERS CHEMICALS, LLC, a Tennessee limited liability company (“Manufacturers Chemicals”), SYNALLOY METALS, INC., a Tennessee corporation (“Synalloy Metals”), BRISTOL METALS, LLC, a Tennessee corporation (“Bristol Metals”), SPECIALTY PIPE & TUBE, INC., a Delaware corporation (“Specialty Pipe”), PALMER OF TEXAS TANKS, INC., a Texas corporation (“Palmer of Texas”), AMERICAN STAINLESS TUBING, LLC, a North Carolina limited liability company (“American Stainless Tubing”, and together with Synalloy, CRI, Synalloy Fabrication, Manufacturers Soap, Manufacturers Chemicals, Synalloy Metals, Bristol Metals, Specialty Pipe and Palmer of Texas, the “Existing Borrowers”), DANCHEM TECHNOLOGIES, INC. (“DanChem”, and together with the Existing Borrowers, the “Borrowers”), the Lenders (as defined in the Credit Agreement) party hereto, and BMO HARRIS BANK N.A., as Administrative Agent for the Lenders (in such capacity, the “Administrative Agent”).  Unless otherwise specified herein, capitalized and/or initially capitalized terms used in this Joinder shall have the meanings ascribed to them in the Credit Agreement.
RECITALS
WHEREAS, the Existing Borrowers, the Lenders party thereto and the Administrative Agent are parties to that certain Credit Agreement, dated as of January 15, 2021 (as amended, restated, supplemented or otherwise modified from time to time prior to the date hereof, the “Existing Credit Agreement”, and as modified by this Joinder, the “Credit Agreement”);
WHEREAS, the Existing Borrowers and the Administrative Agent are parties to that certain Pledge and Security Agreement, dated as of January 15, 2021 (as amended, restated, supplemented or otherwise modified from time to time prior to the date hereof, the “Existing  Pledge and Security Agreement” and as modified by this Joinder, the “Pledge and Security Agreement”);
WHEREAS, the Borrowers have requested that the Administrative Agent and the Lenders, inter alia, permit DanChem to become a Borrower under the Credit Agreement and a Grantor under the Pledge and Security Agreement; and
WHEREAS, the Administrative Agent and the Lenders have agreed to do so, but only on the terms and conditions set forth herein.
NOW, THEREFORE, in consideration of the matters set forth in the above Recitals and the covenants and provisions herein set forth, and other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

AGREEMENT
Section 1Acknowledgements with Respect to Loan Documents.  Effective as of the date hereof (the “Joinder Effective Date”), but subject to the satisfaction of the conditions precedent set forth in Section 2 below, (i) the schedules to the Credit Agreement are hereby deleted in their entirety and replaced with the schedules attached hereto as Exhibit A and (ii) the schedules to the Pledge and Security Agreement are hereby deleted in their entirety and replaced with the schedules attached hereto as Exhibit B.  Notwithstanding anything to the contrary in the Credit Agreement or the Pledge and Security Agreement, (x) none of the assets of DanChem will be included in the Borrowing Base until the Administrative Agent has conducted a Field Exam with respect to DanChem and (y) DanChem shall, within sixty (60) calendar days of the Joinder Effective Date, deliver to the Administrative Agent Control Agreements covering each of its Deposit Accounts, Securities Accounts or Commodity Accounts, if any.  For the avoidance of doubt, the Stock Purchase Agreement dated as of October 22, 2021, between DanChem Holdings, LLC, and Synalloy is deemed to be a Material Contract for the purposes of the Credit Agreement.
Section 2Conditions Precedent to Effectiveness of Amendment.  This Joinder shall become effective upon the satisfaction of each of the following conditions: 
2.1the Administrative Agent shall have received a copy of this Joinder signed by the Loan Parties, the Administrative Agent and the Lenders; and
2.2each of the conditions set forth in Section 5.02 of the Credit Agreement shall have been satisfied or waived in writing by the Administrative Agent. 
Section 3Omnibus Joinder to Loan Documents.  
3.1Each of the Loan Parties (including, for avoidance of doubt, DanChem) hereby acknowledges, agrees and confirms that by its execution of this Joinder, DanChem assumes all the Obligations of a Borrower and a Loan Party under the Credit Agreement and the other Loan Documents (and as a Grantor under the Pledge and Security Agreement and as a Payor and Payee under the Master Intercompany Note), and acknowledges, agrees and confirms that DanChem is a Borrower and a Loan Party and bound as a Borrower and a Loan Party under the terms of the Credit Agreement and the other Loan Documents (and is a Grantor and bound as a Grantor under the terms of the Pledge and Security Agreement and as a Payor and Payee under the Master Intercompany Note), in all cases as if it had been an original signatory to all such agreements.  In furtherance of the foregoing, DanChem hereby grants to the Administrative Agent for the benefit of the Secured Parties (as defined the in the Pledge and Security Agreement) a continuing Lien upon all of its Collateral, whether now owned or existing or hereafter created, acquired or arising and wheresoever located, to secure the prompt payment and performance of all Obligations.
3.2In furtherance of its obligations under Section 6(a) of the Pledge and Security Agreement, DanChem agrees to deliver to the Administrative Agent (i) complete UCC financing statements naming such person or entity as debtor and the Administrative Agent as secured party, and describing its Collateral and such other documentation as the Administrative Agent (or its successors or assigns) may require to evidence, protect and perfect the Liens 
2

created by the Pledge and Security Agreement, as modified hereby (ii) stock certificates representing all of the Equity Interests of DanChem and accompanying stock powers executed in blank.  DanChem acknowledges the authorizations given to the Administrative Agent under the Section 8(b) of the Guaranty and Collateral Agreement and otherwise.
3.3DanChem’s address for notices under the Guaranty and Collateral Agreement shall be the address of the Loan Parties set forth in the Credit Agreement and DanChem hereby appoints the Borrower Agent as its agent to receive notices hereunder.
Section 4Representations and Warranties.  To induce the Administrative Agent and the Lenders to execute this Joinder, each Loan Party hereby represents and warrants to the Administrative Agent and the Lenders as of the Joinder Effective Date as follows:
4.1the execution and delivery of this Joinder and the performance of this Joinder and the Credit Agreement by the Loan Parties has been duly authorized, and each of this Joinder and the Credit Agreement constitutes the legal, valid and binding obligation of each Loan Party, enforceable against such Loan Party in accordance with its terms, except as the enforceability may be limited by bankruptcy, insolvency and similar laws affecting the enforceability of creditors’ rights generally and to general principles of equity;
4.2the execution and delivery of this Joinder and the performance of this Joinder and the Credit Agreement by each Loan Party does not require any consent or approval of any governmental agency or authority (other than (i) any consent or approval which has been obtained and is in full force and effect, or (ii) where the failure to obtain such consent would not reasonably be expected to result in a Material Adverse Effect);
4.3after giving effect to this Joinder and the transactions contemplated hereby and thereby, each of the representations and warranties of each Loan Party set forth in the Credit Agreement, the Pledge and Security Agreement and the other Loan Documents, are true and correct in all respects with the same effect as though made on and as of the date hereof (except to the extent such representations and warranties expressly relate to a specific earlier date, in which case such representations and warranties shall be true and correct in all respects as of such earlier date); and
4.4after giving effect to this Joinder and the transactions contemplated hereby and thereby, no Default or Event of Default has occurred and is continuing or would result from the execution and effectiveness of this Joinder.
Section 5Ratification and Reaffirmation.  Each Loan Party hereby ratifies and confirms the Credit Agreement, the Pledge and Security Agreement and each other Loan Document to which it is a party, each of which shall remain in full force and effect according to their respective terms, as amended hereby. In connection with the execution and delivery of this Joinder and the other Loan Documents delivered herewith, each Loan Party, as borrower, debtor, grantor, mortgagor, pledgor, guarantor, assignor, obligor or in other similar capacities in which such Loan Party grants liens or security interests in its properties or otherwise acts as an accommodation party, guarantor, obligor or indemnitor or in such other similar capacities, as the case may be, in any case under any Loan Documents, hereby (a) ratifies, reaffirms, confirms and continues all of its payment and performance and other obligations, including obligations to 
3

indemnify, guarantee, act as surety, or as principal obligor, in each case contingent or otherwise, under each of such Loan Documents to which it is a party, (b) ratifies, reaffirms, confirms and continues its grant of liens on, or security interests in, and assignments of its properties pursuant to such Loan Documents to which it is a party as security for the Obligations, and (c) confirms and agrees that such liens and security interests secure all of the Obligations. Each Loan Party hereby consents to the terms and conditions of the Credit Agreement and the Pledge and Security Agreement.  Each Loan Party acknowledges  (i) that each of the Loan Documents to which it is a party remains in full force and effect, (ii) that each of the Loan Documents to which it is a party is hereby ratified, continued and confirmed, (iii) that any and all obligations of such Loan Party under any one or more such documents to which it is a party is hereby ratified, continued and reaffirmed, and (iv) that there exists no offset, counterclaim, deduction or defense to any obligations described in this Section 5.  This Joinder shall not constitute a course of dealing with the Administrative Agent or the Lenders at variance with the Credit Agreement, the Pledge and Security Agreement or the other Loan Documents such as to require further notice by the Administrative Agent or the Lenders to require strict compliance with the terms of the Credit Agreement, the Pledge and Security Agreement and the other Loan Documents in the future.
Section 6Release.  In consideration of the agreements of the Administrative Agent and the Lenders contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Loan Party, on behalf of itself and its successors, assigns, and other legal representatives, hereby absolutely, unconditionally and irrevocably releases, remises and forever discharges the Administrative Agent, each Lender and their respective successors and assigns, and their respective present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, administrative agents and other representatives (the Administrative Agent, the Lenders and all such other Persons being hereinafter referred to collectively as the “Releasees” and individually as a “Releasee”), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set off, demands and liabilities whatsoever (individually, a “Claim” and collectively, “Claims”) of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which such Loan Party or any of its successors, assigns, or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the day and date of this Joinder for or on account of, or in relation to, or in any way in connection with the Existing Credit Agreement or any of the other Loan Documents or transactions thereunder or related thereto.
Section 7Miscellaneous.
7.1Signatures; Effect of Joinder.  By executing this Joinder, each of the Loan Parties is deemed to have executed the Credit Agreement, as a Borrower and a Loan Party and the Pledge and Security Agreement, as a Grantor.  All such Loan Parties, Grantors, the Administrative Agent and the Lenders acknowledge and agree that (a) nothing contained in this Joinder in any manner or respect limits or terminates any of the provisions of the Credit Agreement, the Pledge and Security Agreement or any of the other Loan Documents other than as expressly set forth herein and further agree and acknowledge that the Credit Agreement, the 
4

Pledge and Security Agreement and each of the other Loan Documents remain and continue in full force and effect and are hereby ratified and confirmed, and (b) other than as expressly set forth herein, the obligations under the Credit Agreement and the Pledge and Security Agreement and the guarantees, pledges and grants of security interests created under or pursuant to the Credit Agreement, the Pledge and Security Agreement and the other Loan Documents continue in full force and effect in accordance with their respective terms and the Collateral secures and shall continue to secure the Loan Parties’ obligations under the Credit Agreement and any other obligations and liabilities provided for under the Loan Documents.  Except to the extent expressly set forth herein, the execution, delivery and effectiveness of this Joinder shall not operate as a waiver of any rights, power or remedy of the Administrative Agent or the Lenders under the Credit Agreement, the Pledge and Security Agreement or any other Loan Document, nor constitute a waiver of any provision of the Credit Agreement, Pledge and Security Agreement or any other Loan Document, nor constitute a novation of any of the Obligations under the Credit Agreement or obligations under the Loan Documents.  This Joinder does not extinguish the indebtedness or liabilities outstanding in connection with the Credit Agreement, the Pledge and Security Agreement or any of the other Loan Documents.  No delay on the part of the Administrative Agent or any Lender in exercising any of their respective rights, remedies, powers and privileges under the Credit Agreement, the Pledge and Security Agreement or any of the Loan Documents or partial or single exercise thereof, shall constitute a waiver thereof.  None of the terms and conditions of this Joinder may be changed, waived, modified or varied in any manner, whatsoever, except in accordance with Section 11.01 of the Credit Agreement.  
7.2Counterparts.  This Joinder may be executed in any number of counterparts and by the different parties on separate counterparts, and each such counterpart shall be deemed to be an original, but all such counterparts shall together constitute but one and the same instrument.  Delivery of the executed counterpart of this Joinder by telecopy or electronic mail shall be as effective as delivery of a manually executed counterpart to this Joinder.  This Joinder to the extent signed and delivered by means of a facsimile machine or other electronic transmission (including, without limitation, “pdf”, “tif” or “jpg”) and other electronic signatures (including, without limitation, DocuSign and AdobeSign), shall be treated in all manner and respects and for all purposes as an original agreement or amendment and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. No party hereto shall raise the use of a facsimile machine or other electronic transmission to deliver a signature or the fact that any signature or agreement or amendment was transmitted or communicated through the use of a facsimile machine or other electronic transmission as a defense to the formation or enforceability of a contract and each such party forever waives any such defense.  The use of electronic signatures and electronic records (including, without limitation, any contract or other record created, generated, sent, communicated, received, or stored by electronic means) shall be of the same legal effect, validity and enforceability as a manually executed signature or use of a paper-based record-keeping system to the fullest extent permitted by applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act and any other applicable law, including, without limitation, any federal or state law based on or equivalent to the Uniform Electronic Transactions Act or the Uniform Commercial Code.
7.3Severability.  The illegality or unenforceability of any provision of this Joinder or any instrument or agreement required hereunder shall not in any way affect or impair 
5

the legality or enforceability of the remaining provisions of this Joinder or any instrument or agreement required hereunder.
7.4Captions.  Section captions used in this Joinder are for convenience only, and shall not affect the construction of this Joinder.
7.5Entire Agreement.  This Joinder embodies the entire agreement and understanding among the parties hereto and supersedes all prior or contemporaneous agreements and understandings of such Persons, verbal or written, relating to the subject matter hereof.
7.6References.  Any reference to the Credit Agreement or the Pledge and Security Agreement contained in any notice, request, certificate, or other document executed concurrently with or after the execution and delivery of this Joinder shall be deemed to include this Joinder unless the context shall otherwise require.  Reference in any of this Joinder, the Credit Agreement, the Pledge and Security Agreement or any other Loan Document to the Credit Agreement or the Pledge and Security Agreement shall be a reference to the Credit Agreement and/or the Pledge and Security Agreement, as applicable, as amended hereby and as may be further amended, modified, restated, supplemented or extended from time to time.
7.7Governing Law.  THIS JOINDER AND ALL CLAIMS SHALL BE A CONTRACT MADE UNDER AND GOVERNED BY THE INTERNAL LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES.
7.8Payment of Costs and Expenses. The Loan Parties agree, pursuant to the terms of Section 11.04 of the Credit Agreement, to pay on demand all reasonable and documented out-of-pocket expenses of the Administrative Agent incurred in connection with the transactions contemplated hereby to the extent not previously paid or paid on the date hereof (including attorney costs) in connection with the preparation, execution and delivery of this Joinder and the other Loan Documents.
 [Signatures Immediately Follow]
6

IN WITNESS WHEREOF, the undersigned have executed this Omnibus Joinder to Loan Documents as of the date first written above.

BORROWERS:                       
SYNALLOY CORPORATION

By:                                                                   
Name:
Title:

CRI TOLLING, LLC

By:                                                                   
Name: 
Title:   

SYNALLOY FABRICATION, LLC

By:                                                                   
Name:
Title:

MANUFACTURERS SOAP & CHEMICAL CO

By:                                                                   
Name:
Title:

MANUFACTURERS CHEMICALS, LLC

By:                                                                   
Name:
Title:   

Signature page to Omnibus Consent and Joinder Agreement

SYNALLOY METALS, INC.

By:                                                                   
Name:
Title:   

BRISTOL METALS, LLC

By:                                                                   
Name:
Title:   

SPECIALTY PIPE & TUBE, INC.

By:                                                                   
Name: 
Title:   

PALMER OF TEXAS TANKS, INC.

By:                                                                   
Name:
Title:   

AMERICAN STAINLESS TUBING, LLC

By:                                                                   
Name:
Title:  

 
DANCHEM TECHNOLOGIES, INC.

By:                                                                   
Name: 
Title:   
Signature page to Omnibus Consent and Joinder Agreement

						
	ADMINISTRATIVE AGENT:	BMO HARRIS BANK N.A., as Administrative Agent

By:      
Name:  
Title: 

Signature page to Omnibus Consent and Joinder Agreement

						
	LENDER:	BMO HARRIS BANK N.A., as a Lender

By:      
Name:  
Title: 

 
Signature page to Omnibus Consent and Joinder Agreement

EXHIBIT A

Schedules to Credit Agreement

See attached.

    

EXHIBIT B

Schedules to Pledge and Security Agreement

See attached.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]